Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Ascendis Pharma ( (ASND) ) has shared an update.
Ascendis Pharma announced its strategic roadmap for 2025, highlighting key milestones such as the expected U.S. commercial launch of SKYTROFA for adults with growth hormone deficiency pending FDA approval, and plans to expand the availability of YORVIPATH across more European countries. The company reported significant growth in U.S. SKYTROFA market share and revenue projections, alongside developments in their TransCon platform, demonstrating a strong position in the market with a robust product pipeline and financial outlook.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focused on developing innovative therapies for unmet medical needs. The company’s primary products include TransCon hGH and TransCon PTH, which are used for treating growth hormone deficiency and other conditions, and it operates within the global healthcare market.
YTD Price Performance: -6.38%
Average Trading Volume: 415,936
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $7.72B
For detailed information about ASND stock, go to TipRanks’ Stock Analysis page.
